An abnormal BMI in children – be it high or low – can now be associated with impaired lung function, but if their BMI is normalized before they reach adulthood, the impairment can be offset, researchers from Karolinska Institutet report.
MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2) meeting with U.S. FDA and will aim to the IND of Phase III clinical trials. – Biotech Investments
EQS Newswire / 17/01/2024 / 14:25 UTC+8 MegaPro MPB-1523, a MRI contrast agent for focal liver lesion, just completed its End of Phase 2 (EOP2)
January 18, 2024